Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Shattuck Labs Inc
STTK
Healthcare
Biotechnology
Shattuck Labs, Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the CD47/SIRPa macrophage checkpoint interaction and activate the CD40...
costimulatory receptor to induce an antitumor immune response. It is conducting a Phase IA/B clinical trial in patients with acute myeloid leukemia (AML) and HR-MDS. It has completed the Phase IA dose-escalation portion of this clinical trial and are enrolling patients in the Phase IB expansion cohorts evaluating SL-172154 in combination with azacitidine in frontline HR-MDS or frontline TP53 mutant (TP53m) AML. It has developed the ARC platform to address the need for a single therapeutic that consolidates multiple immune functions.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:STTK)
New Post
View:
Posts & Comments
Threaded Posts
(271)
•••
whytestocks
X
Post by
whytestocks
on Oct 27, 2024 10:18am
Bronstein, Gewirtz & Grossman, LLC Is Investigating Shattuck
Just In: $STTK Bronstein, Gewirtz & Grossman, LLC Is Investigating Shattuck Labs, Inc. (STTK) And Encourages Shareholders to ConnectNEW YORK CITY, NY / ACCESSWIRE / October 27, 2024 / Bronstein
...more
(271)
•••
whytestocks
X
Post by
whytestocks
on Oct 23, 2024 3:01pm
Bronstein, Gewirtz & Grossman, LLC Is Investigating Shattuck
Breaking News: $STTK Bronstein, Gewirtz & Grossman, LLC Is Investigating Shattuck Labs, Inc. (STTK) And Encourages Investors to ConnectNEW YORK CITY, NY / ACCESSWIRE / October 23, 2024 / Bronstein
...more
Redefining Neuroprotection: Revive’s Approach to Treating Brain Injury from Nerve Agents
posted Dec 03, 2024 9:00am by
Revive Therapeutics Ltd
-
|
Evaluating Bucillamine as a potential treatment for nerve agent exposure, in partnership with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence. The DRDC is investigating pharmacological compounds, including Bucillamine, that can mitigate nerve agent induced brain injury. ...read more
(271)
•••
whytestocks
X
Post by
whytestocks
on Oct 14, 2024 6:15pm
Bronstein, Gewirtz & Grossman, LLC Encourages Shattuck Labs,
Just In: $STTK Bronstein, Gewirtz & Grossman, LLC Encourages Shattuck Labs, Inc. (STTK) Investors to Inquire about Securities InvestigationNEW YORK CITY, NY / ACCESSWIRE / October 14, 2024
...more
(271)
•••
whytestocks
X
Post by
whytestocks
on Oct 01, 2024 5:15pm
Shattuck Labs Provides Company Update and Announces SL-325,
BREAKING NEWS: $STTK Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway@ Interim clinical data for
...more
(9)
•••
MikeTester
X
Post by
MikeTester
on Aug 02, 2024 1:19pm
Shattuck Labs, Inc. (NASDAQ:STTK): Pioneering Dual-Sided Fus
https://beyondspx.com/2024/07/31/shattuck-labs-inc-nasdaqsttk-pioneering-dual-sided-fusion-proteins-for-transformative-therapies-2/
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
ReGen III Appoints New CEO and President to Accelerate Commercial and Strategic Opportunities
Rig Count Soars as Utilization Surpasses Industry Averages
Learn How this Company is Disrupting Point-of-Care Testing
Unique Battery Metals opportunity in Quebec
Discover Options Trading Strategies to Minimize your Tax Burden
Introducing the NEW DealRoom: Your Gateway to Capital-Raising Investments
Debt-Free Cannabis Company Set for Next Stage of Growth